Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Codiak BioSciences, Inc. (CDAK : NSDQ)

• Company Description    Codiak BioSciences Inc. is a clinical-stage biopharmaceutical company. It is focused on development of exosome-based therapeutics for spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. Codiak BioSciences Inc. is based in CAMBRIDGE, Mass. Number of Employees: 102

• Price / Volume Information    Yesterday's Closing Price: $2.65 Daily Weekly Monthly 20 Day Moving Average: 128,706 shares Shares Outstanding: 22.49 (millions) Market Capitalization: $59.61 (millions) Beta: 4.88 52 Week High: $27.09 52 Week Low: $2.50 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -31.35% -24.77% 12 Week -43.74% -38.95% Year To Date -76.21% -71.71%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 35 CambridgePark Drive Suite 500 - Cambridge,MA 02140 USA ph: 617-949-4100 fax: - investor@codiakbio.com http://www.codiakbio.com

• General Corporate Information    Officers Douglas E. Williams - Chief Executive Officer Steven Gillis - Chairman Linda C. Bain - Chief Financial Officer Karen Bernstein - Director Charles L. Cooney - Director Peer Information Codiak BioSciences, Inc. (CORR.) Codiak BioSciences, Inc. (RSPI) Codiak BioSciences, Inc. (CGXP) Codiak BioSciences, Inc. (BGEN) Codiak BioSciences, Inc. (GTBP) Codiak BioSciences, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 192010106 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/22 Next Expected EPS Date: 08/04/22 Share - Related Items Shares Outstanding: 22.49 Most Recent Split Date: (:1) Beta: 4.88 Market Capitalization: $59.61 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.77 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.93 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 2.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/04/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.11 Price/Cash Flow: - Price / Sales: 2.66 EPS Growth vs. Year Ago Period: 29.41% vs. Previous Quarter: 52.00% Sales Growth vs. Year Ago Period: -3.69% vs. Previous Quarter: 65.05% ROE 03/31/22 - -146.72 12/31/21 - -135.41 09/30/21 - -169.73 ROA 03/31/22 - -40.44 12/31/21 - -40.42 09/30/21 - -42.42 Current Ratio 03/31/22 - - 12/31/21 - 3.32 09/30/21 - 4.50 Quick Ratio 03/31/22 - - 12/31/21 - 3.32 09/30/21 - 4.50 Operating Margin 03/31/22 - -303.65 12/31/21 - -307.14 09/30/21 - -425.30 Net Margin 03/31/22 - -155.37 12/31/21 - -162.01 09/30/21 - -425.30 Pre-Tax Margin 03/31/22 - - 12/31/21 - -162.01 09/30/21 - -425.29 Book Value 03/31/22 - - 12/31/21 - 2.39 09/30/21 - 1.52 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.48 09/30/21 - 0.75 Debt-to-Capital 03/31/22 - - 12/31/21 - 32.22 09/30/21 - 42.71

Powered by Zacks Investment Research ©